Stockscreener 앱 받기
0.97
3.96%
-0.04
시간 외 거래:
.97
전일 마감가:
$1.01
열려 있는:
$1.08
하루 거래량:
313.28K
Relative Volume:
1.29
시가총액:
$85.09M
수익:
-
순이익/손실:
$-21.65M
주가수익비율:
-2.9208
EPS:
-0.3321
순현금흐름:
$-15.84M
1주 성능:
-5.83%
1개월 성능:
-13.39%
6개월 성능:
-49.21%
1년 성능:
-45.20%
1일 변동 폭
$0.9199
$1.08
1주일 범위
$0.9199
$1.10
52주 변동 폭
$0.7709
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
명칭
Cardiol Therapeutics Inc
전화
-
주소
-
CRDL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
0.97 | 85.09M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
146.85 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.19 | 45.61B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.93 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.31 | 15.64B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.25 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-06-26 | 개시 | ROTH MKM | Buy |
| 2024-04-22 | 개시 | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc 주식(CRDL)의 최신 뉴스
Genocea Biosciences (NASDAQ:GNCA) versus Cardiol Therapeutics (NASDAQ:CRDL) Head-To-Head Review - Defense World
(CRDL) Investment Analysis and Advice (CRDL:CA) - news.stocktradersdaily.com
Roth Capital Has Bearish Forecast for CRDL Q1 Earnings - Defense World
Cardiol Therapeutics (CRDL) Projected to Post Quarterly Earnings on Monday - Defense World
Cardiol Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (NASDAQ:CRDL) Earns “Buy” Rating from HC Wainwright - Defense World
Northwestern University enrols first subject in trial of drug for pericarditis - Yahoo
(CRDL) Pivots Trading Plans and Risk Controls (CRDL:CA) - news.stocktradersdaily.com
ardiol Therapeutics Inc. - Baystreet.ca
Cardiol Therapeutics Commences Phase III Trial for CardiolRx™ in Recurrent Pericarditis - TipRanks
Cardiol Therapeutics starts phase III trial for heart drug - Investing.com Australia
Breakthrough Pericarditis Drug Enters Pivotal Phase III Trial After Phase II Success - Stock Titan
3 Reasons to Sell CSV and 1 Stock to Buy Instead - The Globe and Mail
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World
Cardiol Therapeutics Reports Increased Losses Amid Rising Expenses - TipRanks
Long Term Trading Analysis for (CRDL) (CRDL:CA) - news.stocktradersdaily.com
HC Wainwright Has Negative Outlook for CRDL FY2025 Earnings - Defense World
H.C. Wainwright maintains $9 target on Cardiol Therapeutics stock By Investing.com - Investing.com UK
Cardiol Therapeutics (NASDAQ:CRDL) Receives “Buy” Rating from HC Wainwright - Defense World
Cardiol Therapeutics (TSE:CRDL) Reaches New 1-Year Low – Should You Sell? - Defense World
Cardiol Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate - Yahoo Finance
Cardiol Therapeutics advances heart disease treatments By Investing.com - Investing.com South Africa
Cardiol Therapeutics Inc. - menafn
Stocks In Play: Cardiol Therapeutics Inc. - Barchart.com
Cardiol Therapeutics Advances Heart Disease Treatments with Promising Clinical Results - TipRanks
Cardiol Therapeutics advances heart disease treatments - Investing.com
Cardiol Therapeutics Announces Year-End 2024 Update on Operations - Newsfile
Virtu Financial LLC Invests $61,000 in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
Cardiol Therapeutics (TSE:CRDL) Stock Price Down 5% – Time to Sell? - Defense World
Atria Investments Inc Takes Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics Schedules Annual General Meeting for May 2025 - TipRanks
Financial Comparison: Cardiol Therapeutics (NASDAQ:CRDL) versus Cortexyme (NASDAQ:CRTX) - Defense World
Cardiol Therapeutics to Present at TD Cowen Health Care Conference - TipRanks
Cardiol Therapeutics to present at health care conference - Proactive Investors USA
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Newsfile
Can Cardiol's Presentation at Major Healthcare Conference Signal New Clinical Developments? - Stock Titan
Cardiol Therapeutics (TSE:CRDL) Hits New 12-Month LowWhat's Next? - MarketBeat
Quantum Biopharma Announces Completion of the Phase 1 Multiple Ascending Dose Clinical Trial for its Experimental Multiple Sclerosis Drug Lucid-21-302 - Investing News Network
Cardiol Therapeutics (NASDAQ:CRDL) Receives Buy Rating from HC Wainwright - MarketBeat
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.40 Average PT from Analysts - Defense World
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Fa - Newsfile
Promising Potential of Cardiol Therapeutics’ CRD-38 Justifies Buy Rating Amidst Market Need for HFpEF Treatment - TipRanks
JACC data highlights Cardiol’s potential to differentiate in HF space - Yahoo Finance
Cardiol Therapeutics reports heart failure treatment progress By Investing.com - Investing.com Nigeria
Cardiol Therapeutics says study shows benefit of cannabidiol drug in treating heart failure - Proactive financial news
Cardiol Therapeutics reports heart failure treatment progress - Investing.com India
Cardiol Therapeutics Inc (CRDL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.47%
0.69%
자본화:
|
볼륨(24시간):